Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Comment by Rosmorducon Apr 04, 2020 2:35pm
231 Views
Post# 30879250

RE:How another company handled a failed topline result

RE:How another company handled a failed topline resultWe have tell ourselves that we won't get this type of transparency from ACST CEO and BOD.

They will use whatever information they have to their own benefits and have their IR henchman firm tell investors what the company can disclose or not disclose, leaving us in the dark. 

Jan needs to be shown the door right away. This should have been done when Phase 3 results were not met. It would have been the perfect time. But the BOD has failed to do their #1 duty (look out for shareholders). 

Another possibility here might be that they manipulated the phase 3 for failure to artificially sink the shares and get all these cheap options in their pockets. I wouldn't put it past this group. 

Anyway, I'm here for CAPRE as it will be a winner when all the dist settles. I'm convinced of that. By the end of the year, this stock should be back to 3.00-4.00$ if we are not bought out before.  


Bullboard Posts